Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24741219 | 0.85 | TRPA1 (0.37) | PTGS1PTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL25665110 | 0.84 | PTGS1 (0.43) | PTGS1PTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL25512421 | 0.83 | PTGS1 (0.42) | PTGS1PTGS2ALDH1A1KIF11NFE2L2 | |
| SCHEMBL11855670 | 0.82 | KIF11 (0.53) | ALDH1A1KIF11 | |
| SCHEMBL15496932 | 0.80 | AR (0.37) | PTGS1PTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL30874807 | 0.80 | KIF11 (0.51) | PTGS1PTGS2ALDH1A1TDP1KIF11 | |
| SCHEMBL16962162 | 0.80 | PTGS1 (0.43) | PTGS1PTGS2ALDH1A1TDP1KIF11 | |
| SCHEMBL16846737 | 0.80 | KIF11 (0.51) | PTGS1PTGS2ALDH1A1TDP1KIF11 | |
| SCHEMBL1204171 | 0.78 | TP53 (0.42) | PTGS1PTGS2ALDH1A1TP53TDP1 | |
| SCHEMBL30920089 | 0.76 | ALDH1A1 (0.48) | PTGS1PTGS2ALDH1A1TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1866278-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103503-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-10-05 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | PTGS1 1628/4885PTGS2 3254/4885ALDH1A1 1314/4885 |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | OPRL1, CNR1, TRPV1 | PTGS1 228/4885PTGS2 625/4885ALDH1A1 956/4885 |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | TYR, MAPT, DDC | PTGS1 4549/4885PTGS2 4651/4885ALDH1A1 3131/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | PTGS1 1630/4885PTGS2 3232/4885ALDH1A1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.